NCT00326625View on ClinicalTrials.gov

Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)

PHASE2CompletedINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

July 27, 2006

Primary Completion Date

June 17, 2008

Study Completion Date

June 17, 2008

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

40 mg glatiramer acetate

parenteral drug

DRUG

Placebo

Trial Locations (7)

Unknown

Teva Benelux, Haarlem

Teva Benelux, Leuven

Teva France, Paris

Teva Germany, Mörfelden-Walldorf

Teva Israel, Tel Aviv

Teva Italy, Milan

Teva UK, Aylesbury

All Listed Sponsors
lead

Teva Pharmaceutical Industries, Ltd.

INDUSTRY

NCT00326625 - Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter | Biotech Hunter